These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16339700)

  • 1. Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy.
    Derchi G; Forni GL
    Ann N Y Acad Sci; 2005; 1054():471-5. PubMed ID: 16339700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies.
    Derchi G; Forni GL; Formisano F; Cappellini MD; Galanello R; D'Ascola G; Bina P; Magnano C; Lamagna M
    Haematologica; 2005 Apr; 90(4):452-8. PubMed ID: 15820939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Sildenafil increases exercise capacity in low-oxygen settings.
    Ann Intern Med; 2004 Aug; 141(3):I12. PubMed ID: 15289233
    [No Abstract]   [Full Text] [Related]  

  • 4. Sildenafil for enhanced performance at high altitude?
    Rubin LJ; Naeije R
    Ann Intern Med; 2004 Aug; 141(3):233-5. PubMed ID: 15289224
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.
    Ghofrani HA; Reichenberger F; Kohstall MG; Mrosek EH; Seeger T; Olschewski H; Seeger W; Grimminger F
    Ann Intern Med; 2004 Aug; 141(3):169-77. PubMed ID: 15289213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
    Sebkhi A; Strange JW; Phillips SC; Wharton J; Wilkins MR
    Circulation; 2003 Jul; 107(25):3230-5. PubMed ID: 12796132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil in the treatment of pulmonary hypertension.
    Barnett CF; Machado RF
    Vasc Health Risk Manag; 2006; 2(4):411-22. PubMed ID: 17323595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
    Chaudhari M; Vogel M; Wright C; Smith J; Haworth SG
    Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F527-8. PubMed ID: 16244212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM
    Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
    [No Abstract]   [Full Text] [Related]  

  • 13. Sildenafil improves walk distance in idiopathic pulmonary fibrosis.
    Collard HR; Anstrom KJ; Schwarz MI; Zisman DA
    Chest; 2007 Mar; 131(3):897-899. PubMed ID: 17356110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
    Hemnes AR; Champion HC
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):293-300. PubMed ID: 16716091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
    Ghofrani HA; Wiedemann R; Rose F; Olschewski H; Schermuly RT; Weissmann N; Seeger W; Grimminger F
    Ann Intern Med; 2002 Apr; 136(7):515-22. PubMed ID: 11926786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil citrate for the treatment of pulmonary hypertension.
    Hrometz SL; Shields KM
    Drugs Today (Barc); 2006 Dec; 42(12):771-84. PubMed ID: 17285150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
    Lewis GD; Semigran MJ
    Curr Heart Fail Rep; 2004 Dec; 1(4):183-9. PubMed ID: 16036043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Izbicki G; Rosengarten D; Picard E
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.